Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

MJS.V, PWRM, WAT, MSM, BCR - Stock Reports! from CRWEfinance.com

crwefinancelogo2

chartstockalert

___

Waters Corp. (NYSE:WAT) Douglas A. Berthiaume, Chairman, President and Chief Executive Officer, announced that they will speak to the investment community at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on today, January 10th, at 3:00 p.m. pacific time. Interested investors can access the live webcast of the presentation by logging on to Waters Corporation’s website, www.waters.com in the investor relations’ section and clicking on “J.P. Morgan Healthcare Conference.”

Waters Corporation operates as an analytical instrument manufacturer primarily in the United States, Europe, Japan, and Asia. The company designs, manufactures, sells, and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), and mass spectrometry (NYSE:MS).

******

MSC Industrial Direct Co. Inc. (NYSE:MSM) reported financial results for its first quarter ended November 27, 2010. For the fiscal 2011 first quarter, net sales rose 22.9% to $472.8 million, compared with $384.8 million in the prior year period. Operating income increased 51.2% in the fiscal 2011 first quarter to $77.2 million, or 16.3% of net sales, compared with $51.0 million, or 13.3% of net sales, in the prior year period. For the first quarter of fiscal 2011, the Company reported net income of $47.6 million, an increase of 51.4% over net income of $31.4 million in the first quarter of fiscal 2010. Diluted earnings per share in the fiscal 2011 first quarter were $0.75.

MSC Industrial Direct Co., Inc. (NYSEARCA:MSC), together with its subsidiaries, operates as a direct marketer and distributor of metalworking and maintenance, repair, and operations (NYSE:MRO) supplies to industrial customers throughout the United States.

******

Power3 Medical Products, Inc. (OTC:PWRM)

Power3 Medical Products, Inc. recently announced PWRM management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's, to name a few.

In addition, PWRM is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by PWRM several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for PWRM's depressed stock price and have distracted the company from its mission, PWRM plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, PWRM will continue to rigorously defend its position. For example, one such lawsuit involves Neogenomics, Inc., which was recently granted a motion for summary judgment with respect to an amount due under a convertible debenture. PWRM intends to appeal this decision.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers.

With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents.

Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.

PWRM continues to discover new ways to test for Alzheimers, Parkinsons, and Breast Cancer!

To learn more about PWRM visit: http://www.Power3Medical.com

******

http://pennyomega.com/img/mjs.jpg  Majestic Gold Corp. (TSX.V:MJS)

Majestic Gold Corp. is a Vancouver-based; TSX Venture Exchange and Frankfurt Exchange listed gold exploration and development company with a very advanced gold deposit in Shandong province of China. On April 23, 2010, Majestic released an updated NI 43-101- compliant, indicated and inferred gold resource estimate on its Song Jiagou property. At present, Majestic is aggressively pursuing a pre-feasibility study. A recently announced agreement will increase Majestic's effective ownership from 54 to 94 % and has allowed the property to commence production at an initial rate of 1,400 tpd. With a contract that fixes operating costs and allows use of land and equipment, Majestic anticipates to have a positive cash flow, within a matter of months.

Sawayaerdun Project

Sale of Assets 2009:

On April 21, 2009, Majestic announced that it had negotiated an agreement to sell its 72% joint venture interest in the Sawayaerdun gold project in Tianshan Province, China to its Chinese co-venturers for approximately C$7,350,000.

The purchasers, Xinjiang Baodi Mining Ltd. and Brigade No. 2 of Xinjiang Geography & Mine Exploration and Development Bureau, are the Company's dual partners in Xinjiang Majes Mining Inc., the Chinese joint venture company originally established to develop the Sawayaerdun project. On May 14, 2009, the agreement was granted final acceptance by the TSX Venture Exchange.

Location:

The Sawayaerdun Gold Project is located 200 kilometers northwest of Kashi in the western region of Xinjiang Province, China. The property is located in the prolific Tian Shan Gold Belt which hosts numerous world class gold deposits including Muruntau (140,000,000 oz Au) and Kumtor (13,900,000 oz Au). Gold deposits in this belt are commonly structurally controlled, occurring along fault/shear zones within metamorphosed sedimentary rock.

Project Highlights:

  • Historical Resource* >3.0 Mi oz Au reported on license (*not NI 43-101 compliant)
  • Includes >1.4 Mi oz Zone IV
  • Proven geological model - in prolific gold belt
  • Immense gold system (>5km X >2km)
  • Over 120 trenches identifying 22 gold zones on surface
  • 4 main zones with combined surface trace over 11.5 km
  • Previous trenching and drilling results demonstrated good continuity of gold mineralization laterally and down dip

To learn more about Majestic visit:  http://www.majesticgold.net

******

CR Bard Inc. (NYSE:BCR) announced that the company expects net sales growth in the range of 5 to 8 percent in constant currency for the full year 2011. Earnings per share are expected to grow 14 percent over this year's forecasted results, excluding the impact of items that affect the comparability of results between periods. In addition, Bard reiterated its previously announced full year 2010 earnings guidance in the range of $5.50 to $5.54 per share, excluding the impact of items that affect the comparability of results between periods.

C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide.

___

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty-five thousand dollars in cash from a third party for (thirty) days of advertising for Majestic Gold Corp, TSX Venture Exchange (TSX.V:MJS) and the Frankfurt Stock Exchange (FSE:MJT).  Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).